Neuland Laboratories Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Neuland Laboratories Ltd is ₹ 16203 as of 05 May 15:30 . The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 21.1 on March 2021 to 19.7 on March 2025 . This represents a CAGR of -1.36% over 5 years The Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 45131 crore on March 2021 to ₹ 89122 crore on March 2025 . This represents a CAGR of 14.58% over 5 years The revenue of Neuland Laboratories Ltd for the Dec '25 is ₹ 447.76 crore as compare to the Sep '25 revenue of ₹ 516.07 crore. This represent the decline of -13.24% The revenue of Zydus Lifesciences Ltd for the Dec '25 is ₹ 6975 crore as compare to the Sep '25 revenue of ₹ 6232 crore. This represent the growth of 11.93% The ebitda of Neuland Laboratories Ltd for the Dec '25 is ₹ 85.19 crore as compare to the Sep '25 ebitda of ₹ 157.35 crore. This represent the decline of -45.86% The ebitda of Zydus Lifesciences Ltd for the Dec '25 is ₹ 1842 crore as compare to the Sep '25 ebitda of ₹ 2090 crore. This represent the decline of -11.85% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 40.57 crore over 7 quarters. This represents a CAGR of -39.54% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 965.1 crore over 7 quarters. This represents a CAGR of -21.18% The Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 24.28 % on March 2021 to 19.16 % on March 2025 . This represents a CAGR of -4.63% over 5 years .

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Neuland Laboratories Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Neuland Laboratories Ltd or Zydus Lifesciences Ltd?

Market cap of Neuland Laboratories Ltd is 20,788 Cr while Market cap of Zydus Lifesciences Ltd is 91,753 Cr

What are the key factors driving the stock performance of Neuland Laboratories Ltd and Zydus Lifesciences Ltd?

The stock performance of Neuland Laboratories Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Neuland Laboratories Ltd and Zydus Lifesciences Ltd?

As of May 5, 2026, the Neuland Laboratories Ltd stock price is INR ₹16203.05. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹911.85.

How do dividend payouts of Neuland Laboratories Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Neuland Laboratories Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.